A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

To join this study, you need to be at least 18 years old and willing to provide your consent to take part. This study is specifically for people who have been diagnosed with obstructive hypertrophic cardiomyopathy (HCM).

In the UK, this diagnosis would typically follow guidelines from leading heart organisations. Your heart's main pumping chamber (left ventricle) would need to be thicker than usual, and there would be a blockage making it harder for blood to leave your heart (known as a 'gradient'). Your heart's pumping ability should be generally strong, and you should be experiencing symptoms like shortness of breath or chest pain.

As for your current treatment, you might already be taking medicines like beta-blockers, calcium channel blockers, or disopyramide, or starting mavacamten. You might also be eligible if you're not currently on treatment because previous medicines haven't worked for you or you couldn't tolerate them.

As a 'registry study', participation primarily involves allowing researchers to collect information from your routine medical records over time. This means there likely aren't extra visits or procedures specifically for the study. Instead, researchers would track your health status, how your obstructive HCM is managed, the treatments you receive (like mavacamten or other medications), and how your condition progresses during your regular hospital or clinic appointments. This allows them to understand real-world treatment patterns and outcomes without directly interfering with your care. The total duration of your participation would depend on how long the study continues to collect follow-up data.